Annual report
4587.TEDINET S100VITV
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardIFRS
ConsolidatedYes
Data checks21 of 22 passed
Key figures · 159
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥46.7bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥28.7bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥8.1bn | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.6bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥3.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥92.8bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥69.5bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥60.1bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥63.9bn | at 2022-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥36.0bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥29.1bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31d | Cons. | Equity IFRS |
| Net assets / equity | ¥30.5bn | at 2022-12-31d | Cons. | Net assets (5-year summary) |
| Equity (owners) | ¥56.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥40.3bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥25.4bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥48.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥23.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥12.4bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥350m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥8.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥1.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.3bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥264m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥21.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥115.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.41 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥51.13 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥115.68 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.38 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥437.63 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥311.16 | at 2023-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥234.8 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 61.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 58.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.5% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 30.9% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.4% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.4% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 621 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 603 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 569 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 128 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥31.3bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥12.7bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥11.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥20.5bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.4bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥29.8bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥7.0bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥21.1bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥5.8bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥89.7bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥68.2bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥55.2bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.6bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.3bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥34.1bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥27.6bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥55.6bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥40.6bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥29.4bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥25.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥21.2bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥44.6bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥16.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥237m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥162.6 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.85 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.4 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.26 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥428.73 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥312.89 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.0% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.5% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 43.8% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,910,400 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 157 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 153 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 155 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 128 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥741m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥741m |
| Drug Discovery And Development Businessreportable segment | employees | at 2024-12-31 | 157 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥31.3bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥21.0bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2024-12-31 | 464 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥15.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥247m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥47.4bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥46.7bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥741m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥21.2bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥87m |
| Drug Discovery And Development Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥12.7bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥6.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥16.1bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥16.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥475m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥28.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥28.7bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥87m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,490
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash flows from used in financing activities IFRS (5-year summary) | Prior4YearDuration | － | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior3YearDuration | 66067000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior2YearDuration | 20789451000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | 264191000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYearDuration | -2994633000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior4YearInstant | 7149358000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior3YearInstant | 11746529000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior2YearInstant | 5247665000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 19507861000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentYearInstant | 48117933000 | JPY |
| Number of employees | Prior4YearInstant | 128 | |
| Number of employees | Prior3YearInstant | 141 | |
| Number of employees | Prior2YearInstant | 569 | |
| Number of employees | Prior1YearInstant | 603 | |
| Number of employees | CurrentYearInstant | 621 | |
| Net sales (5-year summary) | Prior2YearDuration | 26852430000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 8087436000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 6637884000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 6613242000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 30506085000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant | 60069755000 | JPY |
| Net assets per share (5-year summary) | Prior2YearInstant | 234.80 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 51.13 | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.505 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.244 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 40.62 | |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | -349698000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -27328029000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | 21007032000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 5247665000 | JPY |
| Number of employees | Prior2YearInstant | 569 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 11677253000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 9365964000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 15406109000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 12702965000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 31313392000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 6976277000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 4774477000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 8828041000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 6351644000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 20519287000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 4448357000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 3606407000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 4298050000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 5817622000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 21074258000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -729057000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -470053000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |